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The aim of this study is to develop a simple and specific HPLC method using vitexin as the internal standard 
to investigate the pharmacokinetics of isoquercitrin (ISOQ) after three different doses administrated 
intravenously to rats. The pharmacokinetic parameters were calculated by both compartmental and 
non-compartmental approaches. The results showed that ISOQ fitted a three-compartment open model. 
The values of AUC increased proportionally within the range of 5-10 mg·kg-1. Moreover, a half-life, 
b half-life, aCL, MRT0-t and MRT0→∞ of ISOQ in rats showed significant differences between 20 mg·kg-1 
and other doses, indicating that ISOQ presented dose-dependent pharmacokinetics in the range of 5-10 
mg·kg-1 and non-linear pharmacokinetics at higher doses.
Uniterms: Isoquercitrin/pharmacokinetics/experimental study. High Performance Liquid 
Chromatography. Crataegus pinnatifida Bge. Var major/leaves/phytochemistry.
O objetivo deste estudo é desenvolver um método simples e específico de HPLC usando vitexina como 
padrão interno para investigar a farmacocinética do isoquercitrina (ISOQ) após três doses diferentes 
administradas por via intravenosa a ratos. Os parâmetros farmacocinéticos foram calculados pelas 
abordagens compartimental e não compartimental. Os resultados mostraram que ISOQ se encaixa 
no modelo de três compartimentos. Os valores de AUC aumentaram proporcionalmente na faixa de 
5-10 mg·kg-1. Além disso, a meia-vida, b meia-vida, aCL, MRT0-t and MRT0→∞ de ISOQ em ratos 
mostraram diferenças significativas entre 20 mg·kg-1 e outras doses, o que significa que ISOQ apresenta 
farmacocinética dose-dependente no intervalo de 5-10 mg·kg-1 e farmacocinética não linear em doses 
mais elevadas.
Unitermos: Isoquercitrina/farmacocinética/estudo experimental. Cromatografia líquida de alta eficiência. 
Folhas de Crataegus pinnatifida Bge. Var major/folhas/fitoquímica.
INTRODUCTION
The leaves of Crataegus pinnatifida Bge. var. 
major recorded in the Chinese Pharmacopoeia are a 
well-known traditional Chinese medicine and contain 
many compounds such as chlorogenic acid, vitexin-4’’-
O-glucoside, vitexin-2’’-O-rhamnoside, vitexin, rutin, 
hyperoside, isoquercitrin (ISOQ), and quercetin (Ying et 
al., 2009). In recent years, ISOQ, a flavonol glycoside, has 
attracted a great deal of attention because of its numerous 
biological and pharmacological activities, including anti-
inflammatory activity (Rogerio et al., 2007), antioxidant 
activity in vitro and in vivo (Silva et al., 2009), being 
effective at attenuating the death of RGC-5 cells in 
culture caused by exposure to hydrogen peroxide (H2O2), 
and treating glaucoma (Jung et al., 2010). Moreover, 
many methods including HPLC-UV (Bramati, Aquilano, 
Pietta, 2003), LC-DAD and LC-MS (Maria et al., 2007), 
CZE-UV (Jing et al., 2007), SPE-HPLC (Lai et al., 2007) 
have been reported in the literature for the quantification 
of ISOQ in various herbal medicines. Also, in vitro and 
in vivo analyses of ISOQ have been reported (Chang et 
al., 2005). However, there was little attention paid to 
the pharmacokinetic study of ISOQ after intravenous 
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administration at three different doses, and therefore the 
aim of this study is to investigate the pharmacokinetics 
of ISOQ employing a validated HPLC method with an 
internal standard (I.S.). To the best of our knowledge, this 
is the first report of a pharmacokinetic study following 
the intravenous administration of ISOQ in rats at multiple 
doses.
MATERIAL AND METHOD
Reagents and chemicals
ISOQ and the internal standard, vitexin, were both 
isolated from leaves of C. pinnatifida Bge. var major in our 
laboratory; the purities of both were found to be over 98% 
by HPLC analysis. The leaves were collected in Shenyang, 
Liaoning Province, China and identified by Prof. Bing 
Wang. Voucher specimens (20111020) were maintained 
at the Liaoning University of Tradition Chinese Medicine. 
The chemical structures of ISOQ and vitexin, confirmed 
by 1H and 13C-nuclear magnetic resonance spectroscopy, 
are shown in Figure 1.
The water used in all experiments was purified by 
a Milli-Q® Biocel Ultrapure Water System (Millipore, 
Bedford, MA, USA). Methanol and acetonitrile were both 
of HPLC grade and purchased from Damao (Chemical 
Reagent Plant, Tianjin, China). All other reagents were 
of analytical grade (Jinfeng Chemical Factory, Tianjin, 
China).
Isolation and identification
A sample (5 kg) of the leaves of C. pinnatifida Bge. 
var major was extracted twice using 50 L of 60% aqueous 
ethanol each time. The crude extract was concentrated 
and then passed through a porous-polymer resin (AB-8, 
Tianjin, China). The fraction eluted with 70% ethanol was 
evaporated under reduced pressure to obtain an extract 
and subjected to silica-gel column chromatography 
eluted with ethyl acetate:butanone:formic acid:water 
(6:2:1:0.2). Fractions of similar composition pooled 
on the basis of TLC analysis (UV monitoring at 
365 nm) were repeatedly subjected to silica gel column 
chromatography and sublimated on a Sephadex LH-20 
column to obtain 0.6 g of ISOQ with a purity of 98%, 
which was checked by HPLC. The chemical structures 
of ISOQ confirmed by 1HNMR, 13CNMR and MS data 
were consistent with previous reports (Zhang, Xu, 2001; 
Wang et al., 2004).
Chromatographic system
The analyses were carried out on an Agilent 
1100 series HPLC system (Agilent Technology, Palo 
Alto, CA, USA) which consisted of a quaternary pump 
(G1310A), a vacuum degasser (G1322A), a UV-visible 
spectrophotometric detector (G1314A) and Chemstation 
software (Agilent). The analytes were determined at 30 ºC, 
kept by a column heater (Replete technology, Dalian), on 
an analytical Diamonsil C18 column (150 mm × 4.6 mm 
i.d., 5 μm, Diamonsil, USA) protected by a KR C18 guard 
column (35 mm × 8.0 mm, i.d., 5 μm, Dalian Create 
Science and Technology Co., Ltd., China). The mobile 
phase, which consisted of methanol-acetonitrile-0.1% 
aqueous formic acid (35:5:60, v/v/v), was filtered 
and degassed under reduced pressure before use. All 
chromatographic measurements were performed at 
30 ºC and a flow rate of 1 mL·min-1 with the detection 
wavelength of 360 nm.
Plasma Sample Preparation
10 μL of I.S. (vitexin, 22.6 μg·mL-1), 10 μL of 
acetic acid, and 500 μL of methanol were successively 
pipetted into the 100 μL plasma samples, followed by 
vortex mixing for 1 min. The supernatant was separated 
and evaporated to dryness under a stream of nitrogen at 
40 ºC after being centrifuged at 890 × g for 15 min. The 
residue was constituted in 100 μL of mobile phase and 
centrifuged at 15,092 × g for 10 min. A 20 μL aliquot of 
each supernatant was analyzed by HPLC.
METHOD VALIDATION
Selectivity
Selectivity was shown by comparing chromatograms 
of blank plasma obtained from rats prior to dosing with 
those of corresponding standard plasma samples spiked 
FIGURE 1 - Chemical structures of isoquercitrin (a) and 
vitexin (b).
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with ISOQ and I.S., and plasma samples from rats after 
the intravenous administration of ISOQ.
Preparation of standards and quality control 
samples
Standard stock solutions of ISOQ and I.S. were 
prepared in methanol to yield the concentrations of 160 
and 226 μg·mL-1, respectively. The working solutions were 
prepared with diluted stock solution to concentrations 
over the range of 0.4-160 μg·mL-1. All working solutions 
were stored at 4 ºC. Seven calibrators (0.2, 0.4, 0.8, 2, 5, 
20 and 80 μg·mL-1) of ISOQ were prepared by adding 
standard working solutions (50 μL) and the working 
solution I.S. (22.6 μg·mL-1, 10 μL) to drug-free rat plasma. 
The quality control (QC) samples were prepared at low 
(0.6 μg·mL-1, 3 times of the lower limit of quantitation), 
high (60 μg·mL-1, 75% of the upper limit of quantitation) 
and medium (6 μg·mL-1, near the geometric mean of 
low and high concentration) concentrations in bulk and 
aliquots were stored at -20 ºC prior to analysis.
Linearity and LOD
The linearity was evaluated over the concentration 
range of 0.2-80 μg·mL-1 at seven levels of ISOQ. The 
calibration curves for ISOQ in plasma were generated 
by plotting the peak area ratio of ISOQ to I.S. versus the 
nominal concentrations in the standard plasma samples. 
The regression equation was obtained by weighted (1/c2) 
least square linear regression. The limit of detection (LOD) 
was determined by a signal-to-noise ratio of 3. The lower 
limit of quantification (LLOQ) was defined as the lowest 
concentration of ISOQ in the calibration curves, giving an 
acceptable accuracy (R.E.) within ±20% and a precision 
(R.S.D.) that did not exceed 20%.
Precision and accuracy
The accuracy and precision of the method were 
evaluated with QC samples at three concentrations and 
using five replicates on three consecutive days. The intra- 
and inter-assay precisions were assessed by determining 
the quality control samples at three concentration levels of 
ISOQ (0.6, 6 and 60 μg·mL-1). For the intra-day validation, 
five replicates of the QC plasma samples were analyzed on 
the same day. For the inter-day validation, five replicates 
of the QC plasma samples were analyzed on three different 
days. The precision was expressed as the R.S.D. which 
should be less than 15%, except at the LLOQ where it 
should not exceed 20%; the accuracy of the assay was 
determined by comparing the means of the determined 
ISOQ concentrations with the nominal concentrations. The 
mean percentage deviation from the nominal values was 
expressed as the R.E. which should be within ±15% of the 
nominal value, except at the lower limit of quantification 
where it should not exceed ±20%.
Extraction recovery
The extraction efficiency was determined by 
comparing the peak areas of ISOQ from a blank plasma 
with a known concentration added with the peak areas of a 
blank plasma with the same concentration of ISOQ added 
after protein precipitation (n = 6).
Stability
Five aliquots of unextracted QC samples at low, 
medium and high concentrations were subjected to the 
conditions below. A short-term stability experiment was 
carried out at ambient temperature (25 °C) for 24 h and 
long-term stability was tested by storage at -20 °C for 
one month. QC samples were subjected three freeze 
(-20 °C)-thaw (room temperature) cycles for determining 
freeze-thaw stability. Then, the samples were processed 
and analyzed. The concentrations obtained were compared 
with the nominal values of QC samples.
Animals and pharmacokinetic study
Male Wistar rats (weight 250 ± 20 g) were obtain 
from the Laboratory Animal Center of Liaoning University 
of Traditional Chinese Medicine (Shenyang, China). 
Before the experiments, all rats were kept in a controlled 
environment for one week and had free access to standard 
laboratory food and water. The rats were fasted 12-16 h 
prior to administration of the ISOQ. All animal studies 
were performed according to the Guidelines for the Care 
and Use of Laboratory Animals, which was approved by 
the Committee of Ethics of Animal Experimentation of 
Liaoning University of Traditional Chinese Medicine.
Three groups (five rats/group) were randomly 
assigned to receive ISOQ solution via a tail vein injection 
at doses of 5, 10 and 20 mg·kg-1, respectively. ISOQ was 
dissolved in normal saline containing 20% propylene 
glycol-water (v/v). Blood samples (0.3 mL) were collected 
into heparinized tubes from the vena orbitalis at times 
of 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 and 180 min after 
intravenous administration and then centrifuged at 890 × g 
for 15 min. The obtained plasma was stored at -20 °C until 
analysis.
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RESULTS AND DISCUSSION
Method development
To obtain suitable retention time and good separation 
for the analysis, many mixed solutions were used as the 
mobile phase, such as methanol-water (40:60, 45:55) and 
methanol-acetonitrile-water (30:5:65, 35:5:60, 25:10:65); 
0.1% formic acid was added in the solvent system after 
numerous trials to improve the peak shape and resolution. 
A mixture of methanol-acetonitrile-0.1% aqueous formic 
acid (35:5:60, v/v/v) was finally selected for use in this 
study.
The UV absorption spectra of ISOQ have two 
maximum absorptions at 256 nm and 358 nm and 
that of I.S. at 269 and 331 nm. The interferences from 
endogenous substances in the plasma were observed when 
the wavelength was set at 256 nm; therefore, the detection 
wavelength was set at 360 nm because of no interference 
appeared and it was found to be suitable for the analysis 
of ISOQ and I.S.
A suitable internal standard should be similar to the 
analyte, ISOQ, either structurally or chemically. Hence, 
vitexin-4’’-O-glucoside, vitexin-2’’-O-rhamnoside, 
hyperoside and vitexin were considered as the internal 
standards, with vitexin finally being chosen as the 
internal standard because the optimum resolution and 
retention time could be obtained when compared with 
analyte.
To simultaneously acquire high extraction recovery 
and precision of ISOQ and I.S., several solvents such 
as acetonitrile and methanol were applied to precipitate 
protein in different ratios during the preliminary 
investigation; the highest recovery occurred using 500 μL 
of methanol. 10, 20 and 30 μL of acetic acid were added to 
the plasma to avoid dissociation of the analyte, and a good 
peak shape was finally obtained when 10 μL of acetic acid 
was added to the plasma.
Method validation
Selectivity
To determine the selectivity of this method, blank 
rat plasma, plasma spiked with ISOQ and I.S. and 
plasma samples from rats after intravenous doses of 
ISOQ were analyzed; results are shown in Figure 2. The 
chromatograms showed that there were no interfering 
peaks in the region of the peaks of the analyte and I.S. 
The retention times of ISOQ and I.S. were approximately 
6.8 min and 10.6 min, respectively. The total run time was 
15.0 min.
Calibration curve and quality control samples
The evaluation of the linearity was performed with 
a seven-point calibration curve over the concentration 
range of 0.2-80 μg·mL-1. The slope and intercept of the 
calibration graphs were calculated by weighted (1/c2) least 
squares linear regression. The regression equation of the 
calibration curves was typically: y = 0.2426x - 0.0242, and 
r was 0.9961, where y is the peak area ratio of ISOQ to I.S., 
and x is the plasma concentration of ISOQ. The limit of 
detection (LOD) was 0.06 μg·mL-1, which was determined 
by a signal-to-noise ratio (S/N) of 3. The lower limit of 
quantification defined as the lowest concentration on the 
calibration curve, was 0.2 μg·mL-1 with the precision and 
accuracy within 20%, as verified by repeated analysis.
FIGURE 2 - Representative chromatograms of blank plasma 
(a), plasma spiked with isoquercitrin and vitexin (b) and 
plasma sample 60 min after the intravenous administration of 
isoquercitrin at a dose of 10 mg·kg-1 (c). Peak 1: vitexin; Peak 
2: isoquercitrin.
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Precision and accuracy
The R.S.D.s and R.E.s for intra-day assay of three 
concentrations were in the ranges of 2.3 to 7.2% and -6.3 
to 7.0%, respectively, and that for inter-day were in the 
ranges of 2.8 to 7.7% and 4.0 to 6.2%, respectively. The 
precision (R.S.D.) determined at each concentration level 
is required to not exceed 15% and accuracy (R.E.) was 
within ±15% of the actual value which falls within the 
criteria for the analysis of biological samples according to 
the FDA (USFDA, 2001). The results are shown in Table I.
Extraction recovery
The extraction recoveries of ISOQ at three 
concentrations (0.6, 6 and 60 μg·mL-1) were more than 
91.24 ± 6.93%, and that of I.S. was 98.50 ± 4.82%, 
suggesting that there was negligible loss during extraction, 
which could be attributed to the high solubility of ISOQ 
in methanol and the one-step protein precipitation used in 
the sample preparation.
Stability
The short-term, long-term as well as freeze-thaw 
stabilities of ISOQ in plasma ranged from 92.73 to 99.85%, 
indicating that no significant degradation occurred during 
chromatography, extraction and sample storage processes 
for ISOQ plasma samples.
Pharmacokinetic study
Pharmacokinetic data were processed by 3p97 
software (The Chinese Society of Mathematical 
Pharmacology, Beijing, China). The plasma concentration-
time curves of ISOQ in rats following intravenous 
injection of 5, 10 and 20 mg·kg-1 body weight are shown 
in Figure 3; these demonstrate that ISOQ were eliminated 
rapidly from the plasma. The plasma concentrations of 
ISOQ were detectable only up to 0.75 h in rats at low 
TABLE I - Precision and accuracy of isoquercitrin determination in rat plasma (intra-day: n = 5; inter-day: n = 3 days with 5 replicates 
per day)
Added conc. 
(µg·mL-1)
Intra-day Inter-day
Conc.(µg·mL-1) 
(mean ± SD)
R.S.D. (%) R.E. (%) Conc.(µg·mL-1) 
(mean ± SD)
R.S.D. (%) R.E. (%)
0.6 0.642 ± 0.046 7.2 7.0 0.637 ± 0.049 7.7 6.2
6 5.62 ± 0.24 4.2 -6.3 6.27 ± 0.46 7.4 4.6
60 62.2 ± 1.4 2.3 3.6 62.4 ± 1.8 2.8 4.0
dose, and 3 h in rats at high doses. The pharmacokinetic 
parameters were calculated by both compartmental and 
non-compartmental approaches; all pharmacokinetic 
parameters are given in Table II. The weight of 1/c2 was 
chosen by comparing the goodness of fit for 5, 10 and 
20 mg·kg-1. According to the F test, AIC and R2, a three-
compartment open model gave the best fit to the plasma 
concentration-time curves obtained in rats. The values 
of AUC increased proportionally within the range of 
5-10 mg·kg-1. Additionally, the pharmacokinetic results 
of α half-life, β half-life, aCL, MRT0→t and MRT0→∞ 
showed significant differences between 20 mg·kg-1 and 
other doses. The α half-life at a dose of 20 mg·kg-1 was 
more than those after other doses, indicating that the 
distribution of ISOQ in rats was slower at 20 mg·kg-1. 
The greater β half-life, MRT0→t and MRT0→∞ at 20 mg·kg-1 
suggested that ISOQ was subjected slower elimination 
than other doses. According to the above results, ISOQ 
presented dose-dependent pharmacokinetics in the range 
of 5-10 mg·kg-1 and non-linear pharmacokinetics at higher 
FIGURE 3 - Mean plasma concentration-time curves of 
isoquercitrin in rats (mean ± S.D., n = 5) after the intravenous 
administration of doses of 5, 10 and 20 mg·kg-1. These sampling 
points, which could not be detected, i.e. plasma concentrations 
under the LOQ, were not included in the mean plasma 
concentration-time curves.
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doses, mainly because the metabolic enzyme of the drug or 
carrier of drug membrane-permeable process is saturated 
at high concentrations; i.e. the catalytic capability of 
metabolic enzymes or the transportation capability of a 
carrier is saturated when the dosage and the concentration 
in vivo exceed a certain limit (Leon, Andrew, 1993).
CONCLUSIONS
A simple and specific HPLC method was developed 
for the determination of ISOQ in rat plasma, which was 
successfully applied to an in vivo kinetic study in rats. 
ISOQ presented dose-dependent pharmacokinetics in the 
range of 5-10 mg·kg-1 and non-linear pharmacokinetics at 
higher doses. The validated method contributes not only 
to the determination of ISOQ in rat plasma but also to our 
understanding of the pharmacokinetic characteristics of 
ISOQ over the multiple doses in rats after intravenous 
administration.
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